4.1 Article

Effects of a Ketogenic Diet on Symptoms, Biomarkers, Depression, and Anxiety in Parkinson's Disease: A Case Study

期刊

CUREUS JOURNAL OF MEDICAL SCIENCE
卷 14, 期 3, 页码 -

出版社

CUREUS INC
DOI: 10.7759/cureus.23684

关键词

neurodegenerative disease; metabolic health; integrative and functional nutrition; low carb; ketogenic diet; symptoms; anxiety; depression; biomarkers; parkinson's disease

向作者/读者索取更多资源

The ketogenic diet is gaining popularity as a safe and effective alternative or adjunct therapy for Parkinson's disease and other neurodegenerative diseases. It has been found to improve biomarkers of health, symptoms of depression, anxiety, and PD symptoms in patients. Further clinical trials are recommended for more generalized results.
The ketogenic diet has grown in popularity as an alternative or adjunct to medication therapy for Parkinson's disease (PD) and other neurodegenerative diseases (NDD). Traditional medication therapies often fail to produce desired improvements in PD symptoms and can have little or no effect on symptoms of depression and anxiety that often accompany a PD diagnosis. We document a case study involving a 68year-old female with PD stage I and a history of mild symptoms of anxiety and depression. The subject adopted a traditional ketogenic diet (fats 70%; protein 25%; carbohydrates 5%) for 24 weeks. Baseline, 12-week and 24-week biomarkers (lab results), and scores on a depression scale, anxiety scale, and the Unified Parkinson's Disease Rating Scale (UPDRS) (parts I-Ill) for PD symptoms were compared. Significant improvements were observed in all health biomarkers, including a reduction in HbA1C, C-reactive protein (CRP), triglycerides, and fasting insulin, along with weight loss and reduction in cardiac risk factors. Improved high-density lipoprotein (HOW levels were seen at 12 weeks and 24 weeks, along with improved anxiety symptoms at the 12-week and 24-week mark. Minimum improvement was seen on depression scale scores at 24 weeks. Based on our findings, the ketogenic diet is safe and effective for improving biomarkers of health, symptoms of depression, anxiety, and PD symptoms in patients with stage I PD. We recommend further clinical trial studies for more generalizable results.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据